NTT was established in January 2003 as a US Company with outstanding Business Development and professional R&D management  teams. It's main purpose is to develop and commercialize novel topical drug technologies. Novel Therapeutic Technologies is a joint venture with the Hebrew University of Jerusalem. NTT’s key people are experienced in international business management and have recognized scientific credibility. The company’s core technology - The Ethosome Delivery System originates from  the Medical department of the Hebrew University of Jerusalem,a world renowned research Institution with three Nobel Price Winners. Ethosomes systems provide an effective solution for dermal and transdermal delivery of active pharmaceutical and cosmetics compounds.

The Ethosome Drug Delivery System was invented by a group of scientists lead by Prof. Elka Touitou, a worldwide recognized expert in transdermal delivery,  from the School of Pharmacy at Hebrew University of Jerusalem. Prof. Touitou was the president of the Israel Controlled Released Society (CRS) and is currently a board member. 

The global transdermal drug delivery market is expected to reach an estimated $21.5 billion by 2010 and $31.5 billion by 2015 (Transdermal Drug Delivery - Technologies, Markets, and Companies, Jain PharmaBiotech, May 2005). It has been recognized that due to the Ethosome’s advantages over existing transdermal drug delivery technologies, NTT is well positioned in this market.

The Ethosome is a passive,non-invasive drug delivery  technology which delivers a wide range of drugs with varying chemical properties to and past the skin, and is well suited for a large number of applications in the pharmaceutical, biotechnological & other healthcare markets.

Ethosomes are composed from safe and approved materials for pharmaceutical and cosmetic use and take the form of creams ,gels, patches, spray and other semi solid forms, which have the advantage of high levels of patient compliance.

Products using the technology are already on the market and are generating revenues.

The Ethosome technology, which has proven feasibility both scientifically and commercially, is the subject of international patents and patent applications.

NTT’s proprietary technology offers opportunities for revenues over the short, medium and long terms.